anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1490166 Blood transfusion HAEMONETICS CORP 13 Aug 1975 [15 Aug 1974 15 July 1975] 33802/75 Heading A5R [Also in Divisions Bl and B2] In a method of withdrawing whole blood from a donor, centrifuging the blood and returning the separated red cells to the donor, the whole blood is withdrawn from the donor by means of a phlebotomy needle 13 with simultaneous addition of anticoagulant by means of a pump 16 and tubing 15, and is fed by means of a pump 14 and a tubing 12 to the bottom of a lower red cell reservoir of a centrifuge bowl 10 which is rotated as the blood is delivered to it. During centrifuging the plasma fraction is separated and transferred via plasma ducts to an upper plasma reservoir of the bowl. After a predetermined amount of blood has been withdrawn from the donor, rotation of the bowl is stopped and the red cells are returned to the donor by reversing the flow through pump 14. An amount of saline or other volume extender may be pumped via tubing 17 and a pump 18 simultaneously with the cells to compensate for the loss of blood volume represented by the plasma. The cycle may be repeated to accumulate additional plasma in the plasma reservoir. After all the red cells have been returned to the donor, the tubing and needle connection is broken and the plasma reservoir is sealed off and severed from the red cell reservoir which is discarded. The plasma is then frozen in the reservoir in which it was collected. Alternatively, the plasma may be transferred to a separate plastics bag.
Previous studies have highlighted the need to offer targeted effective interventions to strengthen the wellbeing of all family members in families with children with neurodevelopmental disorders (NDD). Interventions for this target group requires development and research. A new family intervention, Dialogical Family Guidance (DFG) was tested in this study.

Fifty families of children with NDD were randomized into two intervention groups. Intervention group I were delivered DFG immediately, and Intervention group II were delivered DFG after three months. Family functionality, health and support (FAFHES), SDQ and the 5-15-questionnaire and DFG parent questionnaires were used to collect data at baseline, after three and six months. Fifty families were invited to the study. Thirty-four families completed the study. A comparison were made between Intervention group I and II.
Pharmacological treatments (i.e., melatonin) and non-pharmacological therapies (e.g., parent-based sleep education programs and behavioural interventions) have been found to result in improved sleep in children and adolescents with autism spectrum disorder (ASD). However, there are several limitations to these treatment approaches, including concerns about the possible side-effects and safety, high-cost and uncertainties of long-term effects. Physical activity (PA) intervention is a promising behavioural intervention that has received increasing attention. However, the effects of PA intervention on sleep are still unclear in this clinical group. This study aimed to synthesize available empirical studies concerning the effects of PA interventions on sleep in children and adolescents with ASD. Following PRISMA guidelines, seven electronic databases: APA PsychInfo, CINAHL Ultimate, ERIC, MEDLINE, PubMed, SPORTDiscus, and Web of Science, were searched from inception to March 2023. Randomized controlled trials/quasi-experimental designs with comparison groups were included. Initially, 444 articles were identified, 13 articles underwent systematic review, and 8 studies with control groups and sufficient statistical data were selected for meta-analysis. Compared to no-treatment control groups, PA interventions had a large positive effect on parent-reported general sleep problems, night awakenings, sleep resistance, sleep duration and actigraphy-assessed sleep efficiency in children and adolescents with ASD.
Allergic rhinitis (AR) is a non-infectious inflammatory disease of the nasal mucosa mediated by Immunoglobulin E after exposure to allergens. AR has become a major chronic inflammatory disease of the respiratory tract, which has a serious impact on the quality of life of patients and social economy. The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.). However, even if patients are treated completely according to the standard diagnosis and treatment strategy, a considerable number of patients still do not achieve satisfactory treatment results. Arbidol is a medicine for the prevention and treatment of influenza. Based on our previous laboratory data, Arbidol may inhibit molecular targets involved in the pathogenesis of AR. In order to make the treatment of AR more effective, timely and convenient, this study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
OBJECTIVES: I. Compare the efficacy of CYTOIMPLANT (intratumor implants of allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture) vs gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic cancer. II. Compare the overall survival, progression free survival, objective tumor response, time to treatment failure, and quality of life of these patients. III. Compare the safety and toxicities of CYTOIMPLANT vs gemcitabine in these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patients are randomly assigned (2:1 ratio in favor of CYTOIMPLANT arm) to one of two treatment arms. Arm I: Patients receive gemcitabine IV weekly for 7 weeks, followed by 1 week of rest. In subsequent courses, patients then receive gemcitabine IV weekly for 3 weeks followed by a week of rest. Courses are repeated every 4 weeks in the absence of disease progression or unacceptable toxicity. Arm II: Patients undergo leukapheresis to collect lymphocytes. Patient lymphocytes are mixed with donor lymphocytes at the sponsor labs. The mixture is implanted into the tumor using endoscopic ultrasound guided fine needle injection. This process may be repeated in the fifth month using different donor's lymphocytes. Follow up assessments may include physical exams, lab tests, CT scans, and quality of life assessments at 4 weeks and at 3, 5, 7, 9, and 12 months from the date of randomization. Patients are then contacted every 3 months to assess status.

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.
A buprenorphine formulation comprises a suspension of 5-20 wt% of buprenorphine in water, wherein the buprenorphie is in particulate form with an average particle size of less than 200Âµ, preferably less than 20Âµ. The formulation may further comprise a water soluble polymer selected from the group consisting of polyethylene glycol (PEG), carboxymethyl cellulose (CMC), polyvinyl pyrrolidone (PVP), polyvinyl acetate (PVA) and dextran, preferably PEG. The composition may also comprise: a non-ionic surfactant selected from the group including Tween 20(RTM), Tween 80(RTM), poloxamers and phospholipids; pharmaceutically acceptable salts or sugars to adjust the tonicity of the formulation and/or preservatives, preferably selected from the group consisting of methylparaben, propylparaben and benzyl alcohol. A formulation comprising a buprenophine free base suspension in PEG3350, Tween 80(RTM) and sodium chloride aqueous solution is exemplified. The composition is preferably useful in treatment of opioid dependence or pain relief. Also outlined are methods for formulating the composition.
Mothers will bring their infants to the Clinical Research Center where they will be escorted to a private room. Participants will proceed to feed their infant a typical liquid meal (i.e. breastmilk or formula). Within 15 minutes of completion of the feed, infants will be placed in the prototype infant reclining device at either 0, 10, 18, or 28 degrees of incline. Infants will spend 15 minutes at each level of incline in a randomly assigned order. During this time period that each infant is under observation the infant may be entertained/distracted/comforted with white noise, music or other forms of distraction as determined by the mother or study team. Mothers may touch/caress their infant or use a pacifier to soothe infant as needed so long as each 15 minute segment is completed. Following each 15 minute segment, a "washout" period will be used such that the next 15 minute segment will not begin for a minimum of 1 minute to a maximum of 5 minutes in duration before the next incline position is begun. This allows for a clean start and stop period for each 15 minute segment that is not impacted by either the prior position or the change to the new position. This also allows mothers or study staff to pick up and comfort the infant.

During each of the four 15 minute segments, infants will be monitored using the Masimo RAD-97 pulse oximeter with data continuously collected regarding oxygen saturation and heart rate in 2-second intervals. The oxygen saturation probe will preferably be attached to a big toe, but can be placed in alternative spots consistent with usual clinical care such that a consistent reading of heart rate and oxygen saturation are recorded. A study coordinator will complete a data collection form for each segment characterizing whether GER occurred (spit-up into mouth or outside of mouth), the number of GER episodes as well as a subjective assessment of degree crying/fussing, hiccups, back arching, and breathing difficulty. The coordinator will also have a timer to measure the duration of crying in each position. Infants will be video recorded as a backup method for symptom assessment and for qualitative assessments by the study sponsor.
FIELD: chemical or physical processes.SUBSTANCE: invention can be used in production of varnishes, printing inks, inks, polymer materials, glass, ceramic products and compositions of decorative cosmetics. Disclosed is a metallic lustrous pigment based on coated aluminum plates. Aluminum plates have a monolithic structure and are surrounded by at least one coating B of iron (III) oxide, wherein the weight fraction of iron (III) oxide in the coated aluminum plates is at least 65 wt. %. Between the surface of the aluminum plates and the coating B there is an additional coating A made of at least one low-refractive metal oxide, which has a refraction index not exceeding 1.8, selected from a group consisting of SiO2, B2O3, MnO2, MgO, GeO2and Al2O3. Aluminum plates have thickness in range of 1 nm to 30 nm, coating B has thickness in range of 100 nm to 300 nm. Also disclosed is a version of a metallic lustrous pigment, a method of producing said pigments and use of the pigment.EFFECT: group of inventions enables to obtain metallic lustrous pigments with high opacity and low flammability.10 cl, 1 tbl, 4 dwg, 3 ex
Patients will be randomized to one of two arms: palifermin with Lupron, and control. The control arm consists of a standard TCD allo-HSCT without the addition of palifermin or Lupron.

Patients randomized to receive Lupron will receive a three month depot dose 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Patients assigned to receive palifermin will receive this drug at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction. The preparative regimen to be used for transplants will consist of: hyperfractionated TBI administered in 11 doses over 4 days for a total of 1375 cGy, thiotepa 5 mg/kg/day IV x 2 days and cyclophosphamide with mesna prophylaxis 60 mg/kg/day IV x 2 days. All patients will receive ATG for two doses prior to transplant, except recipients of mismatched grafts (in the GVHD vector) will receive three doses. G-CSF mobilized CD34 PBSCs obtained from the HLA compatible donor will be infused on day 0. Patients assigned to receive palifermin will receive three additional daily doses of the drug, the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 and d+2. Patients assigned to receive Lupron will receive a further 3-month depot injection approximately 3 months (+/- one week) post the first dose. Supportive care will be administered as per the BMT Service guidelines. The conditioning regimen may be modified to allow an extra day during conditioning or prior to the graft infusion if required by donor and/or patient scheduling restrictions.
Functional constipation (FC) in children is a common gastrointestinal (GI) disorder with a worldwide prevalence ranging from 0.7% to 29.6%. Complaints include infrequent bowel movement, painful defecation due to hard and/or large stools, fecal incontinence, and abdominal pain. Although the condition is rarely life-threatening, it strongly impairs quality of life. Oligosaccharides have been shown to relieve constipation symptoms in young adults and elderly. However, sufficient evidence is lacking linking oligosaccharides intake to improve symptoms in children with FC. The investigators hypothesize that oligosaccharides might be able to relieve symptoms of constipation in young children as well, among which softening stools.
This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence. PEG dose will be adjusted in the same manner as in group a, but this group will also receive daily treatment with low volume trans anal irrigation.
PURPOSE:To determine an enzyme labeled transforming gross factor (TGF) efficiently by reacting the TGF and a TGF antibody with sample liquid, and separating an enzyme labeled TGF-TGF antibody coupler and unreacted TGF. CONSTITUTION:The sample liquid whose content of TGF is to be measured, such as the urine or serum of a man, and enzyme TGF and TGF antibody are brought into competing reaction by incubation in an immunity reactive medium, e.g. phosphoric acid buffer or veronal buffer solution at about 4-5 deg.C for about 15-72 hours. Then, B-F separation is performed to separate an immunity coupling part, specially, enzyme labeled TGF-TGF antibody coupling part B and an unreacted free part which is not coupled, specially, the free part F of unreacted enzyme labeled TGF. Then, the amount of the enzyme label of either of the separated parts is determined. Thus, the enzyme labeled TGF and TGF antibody obtained by using human TGF are used to determine the TGF in sample liquid easily and extremely accurately, deciding on cancer effectively.
Community-based accompaniment with directly observed antiretroviral therapy (DOT-HAART) may improve adherence and clinical outcomes among impoverished individuals starting HAART in resource-poor settings. Furthermore, the utilization of community health workers may build social capital. This is cluster-randomized trial, with randomization at the level of health centers. Individuals in both intervention and control clusters will receive community-based adherence support (monthly adherence visits) and standard care. In addition, individuals residing in intervention clusters will receive 12 months of community-based DOT-HAART. We will enroll patients as well as community members (health providers, treatment supporters, and community health workers) to assess individual and community-level outcomes.
PURPOSE:A feed for domestic animals that contains saccharides mainly composed of fructoligosaccharide, thus improving diarrhea in domestic animals occurring oftentimes in the weaning period to increase body weight efficiently. CONSTITUTION:The objective domestic feed is prepared by adding a saccharide mainly containing fructoligsaccharide resulting from action of fructosyl transferase on sucrose, to general feed for domestic animal by 0.1-5pts.wt. per 100pts. wt. When domestic animals are fed with the resultant product, diarrhea and loose feces, which are observed in many infant animals in the weaning period are remarkably reduced to increase greatly the intake of the feed. Thus, their body weight remarkably increases with improved feed efficiency.
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression.
<P>PROBLEM TO BE SOLVED: To provide an article or a product which is a moist wipe fibrous article or product retaining a liquid composition on a substrate utilizing advantages thereof while avoiding disadvantages of wipe fibers of both conventionally used wet and dry types.  <P>SOLUTION: The article comprises the substrate and the liquid composition impregnated into the substrate. The impregnated substrate contains at least 20 wt.% of water and the liquid composition is impregnated in an amount of 0.5-2.0 g based on 1 g of the substrate. The substrate contains at least 30% of hydrophilic fibers and comprises a nonwoven fabric substrate or a woven fabric substrate. The article has ≤10% of settling variation. Furthermore, the settling variation is determined as follows. Thirty substrates impregnated with the liquid composition are stacked upon one another to form a stack. The resultant stack is allowed to stand for 2 days and a first average weight of the topmost five substrates and a second average weight of the bottommost five substrates in the stack are measured. Both of the first average weight and the second average weight are regulated to vary ≤10% from the original weight of the substrates impregnated with the liquid composition.  <P>COPYRIGHT: (C)2004,JPO
The method involves assigning an image data to a data type out of several possible data types. A loading strategy out of several data-type-specific loading strategies assigned to the identified data type is selected. The loading strategy is selected on the basis of the context data. The selected loading strategy is utilized for loading the image data. The data type is assigned on the basis of the metadata. The loading strategy is determined relating to imaging regions of interest identified in a preceding assessment. An independent claim is included for a device for loading medical image data.
The invention discloses a denture cleansing tablet and a preparation method thereof. The denture cleansing tablet is prepared from the following raw materials in percentage by mass: 30-40% of traditional Chinese medicine extract, 15-25% of sodium bicarbonate, 5-8% of adhesive, 1-2% of lubricant and the balance of filler. The traditional Chinese medicine extract is prepared from nutgall, fresh chufa, fresh green lemon, roughhaired holly root, eucalyptus, schisandra fruit, radix ophiopogonis, Glehnia Root, radix polygonati officinalis, burdock fruit, fresh snake gourd, trichosanthes kirilowii Maxim root, gardenia kernel, giant knotweed, Fructus Forsythiae and honey-fried licorice root. The denture cleansing tablet is convenient to use, and is capable of effectively cleaning the denture and killing pathogens. The denture soaked and cleaned by the denture cleansing tablet can be directly put on without being flushed with clean water. The denture cleansing tablet can effectively prevent and treat denture stomatitis, and effectively prevents bacteremia and other complications.
Acute myocardial infarction (AMI) causes acute cardiac cell death when oxygen supply is disrupted. Improving oxygen flow to the damaged area could potentially achieve the to prevent cell death and provide cardiac regeneration. Here, we describe the production of oxygen-producing injectable bio-macromolecular hydrogels from natural polymeric components including gelatin methacryloyl (GelMA), hyaluronic acid (HA) loaded with catalase (CAT). Under hypoxic conditions, the O2-generating hydrogels (O2 (+) hydrogel) encapsulated with Mesenchymal stem cells (MSCs)-derived-exosomes (Exo- O2 (+) hydrogel) released substantial amounts of oxygen for >5 days. We demonstrated that after 7 days of in vitro cell culture, exhibits identical production of paracrine factors compared to those of culture of rat cardiac fibroblasts (RCFs), rat neonatal cardiomyocytes (RNCs) and Human Umbilical Vein Endothelial Cells (HUVECs), demonstrating its ability to replicate the natural architecture and function of capillaries. Four weeks after treatment with Exo-O2 (+) hydrogel, cardiomyocytes in the peri-infarct area of an in vivo rat model of AMI displayed substantial mitotic activity. In contrast with infarcted hearts treated with O2 (-) hydrogel, Exo- O2 (+) hydrogel infarcted hearts showed a considerable increase in myocardial capillary density. The outstanding therapeutic advantages and quick, easy fabrication of Exo- O2 (+) hydrogel has provided promise favourably for potential cardiac treatment applications.
BACKGROUND: Assessing bias (estimated - measured) is key to evaluating glomerular filtration rate (GFR). Stratification by subgroups can indicate where equations perform differently. However, there is a fallacy in the assessment of two instruments (e.g., eGFR and mGFR) when stratifying on the level of only one of those instruments. Here, we present statistical aspects of the problem and a solution for GFR stratification along with an empirical investigation using data from the CKiD study.
METHODS: Compared and contrasted biases (eGFR relative to mGFR) with 95% confidence intervals within strata of mGFR only, eGFR only, and the average of mGFR and eGFR using data from the Chronic Kidney Disease in Children (CKiD) study.
RESULTS: A total of 304 participants contributed 843 GFR studies with a mean mGFR of 48.46 (SD = 22.72) and mean eGFR of 48.67 (SD = 22.32) and correlation of 0.904. Despite strong agreement, eGFR significantly overestimated mGFR when mGFR < 30 (+ 6.2%; 95%CI + 2.9%, + 9.7%) and significantly underestimated when mGFR > 90 (-12.2%; 95%CI - 17.3%, - 7.0%). Significant biases in opposite direction were present when stratifying by eGFR only. In contrast, when stratifying by the average of eGFR and mGFR, biases were not significant (+ 1.3% and - 1.0%, respectively) congruent with strong agreement.
CONCLUSIONS: Stratifying by either mGFR or eGFR only to assess eGFR biases is ubiquitous but can lead to inappropriate inference due to intrinsic statistical issues that we characterize and empirically illustrate using data from the CKiD study. Using the average of eGFR and mGFR is recommended for valid inferences in evaluations of eGFR biases.
Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
Participants were administered SoC therapy defined as aflibercept (2mg/50mcL) first, followed by the Sham injection 15 minutes later. Administration occurred EOM for a total of 6 doses during the 12-month study period.